Applications

Daily topical NAD⁺ precursor therapy designed to restore UV-depleted cellular energy, improve skin resilience, and slow biological skin ageing under unavoidable UV exposure.

Topical field therapy addressing skin field cancerization through sustained epidermal exposure, supporting long-term prevention strategies beyond oral supplementation.

Fast-acting topical treatment capable of resolving visible lesions while treating surrounding subclinical damage, integrated into routine skin care.

First-in-class exploration of topical PARP-1 inhibition, achieving local therapeutic concentrations while avoiding systemic toxicity.

Delivery of actives that restore ceramide synthesis, reduce inflammation and itch, and improve tolerance in compromised skin.

Niacinamide is already well recognised in blemish-prone skin, but its real potential depends on effective delivery. Limeway’s 10% NAM platform is designed to achieve sustained epidermal exposure while supporting barrier repair, calming inflammation, and improving the appearance of post-blemish skin. The result is a science-led opportunity in acne-prone skin that combines credibility, cosmetic elegance, and adherence-focused formulation design.

Targeted therapy to reduce UV-induced hyperpigmentation, improve clarity, and reverse senescent keratinocyte behaviour.

Formulations engineered for long-term use, combining pharmaceutical efficacy with cosmetic-grade aesthetics to support adherence-dependent outcomes.